By Morgan Nwanguma
A genetic target once considered “undruggable” in pancreatic cancer has finally been successfully targeted, and a new treatment has nearly doubled survival in a landmark clinical trial.
For decades, pancreatic cancer has remained one of the deadliest forms of cancer, with limited treatment options and poor survival rates. A new drug, daraxonrasib, targets mutations in the KRAS gene – a key driver of most pancreatic tumours, overcoming a challenge that many scientists believed was impossible to solve.
For patients diagnosed with metastatic pancreatic cancer between 2015 and 2021, survival outcomes have been particularly grim, with approximately 97% dying within five years of diagnosis.
Pancreatic cancer is especially difficult to treat because there are no reliable screening tests, and the disease often causes few or no symptoms in its early stages. By the time symptoms such as abdominal pain or jaundice – a yellowing of the skin and eyes appear, the cancer has frequently spread to other parts of the body.
As a gastrointestinal oncologist involved in early-phase clinical trials, I have witnessed the urgent need for more effective therapies. For many years, directly targeting the biological mechanism responsible for most pancreatic cancers remained out of reach.
That outlook is now changing. In a major clinical trial, daraxonrasib nearly doubled overall survival in patients with advanced pancreatic cancer, extending median survival from 6.7 months to 13.2 months. The treatment also reduced the risk of death by 60% compared with standard chemotherapy.
Why Pancreatic Cancer Has Been So Difficult to Treat
Standard treatment for advanced pancreatic cancer has traditionally relied on chemotherapy, which works by destroying rapidly dividing cells. Although chemotherapy can slow disease progression, pancreatic cancer cells often develop resistance, limiting the treatment’s long-term effectiveness.
The disease is driven largely by its genetics. More than 90% of pancreatic tumours harbour mutations in the KRAS gene, which produces proteins that regulate cell growth. When KRAS is mutated, it becomes permanently switched on, continuously instructing cancer cells to grow and divide.
For decades, researchers considered KRAS “undruggable” because the protein’s smooth surface lacks the binding pockets that conventional drugs typically need to attach and block its activity.
As a result, treatment has largely depended on broad-acting chemotherapy drugs that can damage healthy tissues alongside cancer cells, often causing significant side effects.
What Is Daraxonrasib?
Daraxonrasib is an oral medication taken once daily that works differently from earlier approaches. Rather than binding directly to KRAS, the drug attaches to cyclophilin A, a cellular protein involved in folding other proteins into their functional three-dimensional structures.
The resulting protein complex can then bind to active KRAS and prevent it from sending signals that drive tumour growth.
The drug’s developer, Revolution Medicines, presented findings from a Phase 3 clinical trial involving 500 patients with previously treated metastatic pancreatic cancer on May 31, 2026.
Compared with standard chemotherapy, patients who received daraxonrasib experienced substantially longer survival, with median overall survival increasing from 6.7 months to 13.2 months.
The most commonly reported side effect was a skin rash, affecting more than 86% of participants. Other frequent side effects included stomatitis, which causes painful mouth sores and inflammation, as well as diarrhoea, nausea, and vomiting.
Despite these effects, patients receiving daraxonrasib were less likely to discontinue treatment because of severe side effects than those receiving chemotherapy. They also reported improved quality of life and reduced pain.
What Happens Next?
By successfully targeting the genetic alteration responsible for most pancreatic cancers, researchers have shown that precision therapies can be effective against a disease once considered beyond the reach of targeted treatment.
The next step is regulatory review. Revolution Medicines plans to use the Phase 3 findings to seek approval from the U.S. Food and Drug Administration and other regulatory agencies worldwide.
Given the significant survival benefits observed in patients with advanced disease, the drug could qualify for expedited review pathways. If approved, daraxonrasib may become available to patients within months.
The findings are also expected to reshape future pancreatic cancer research. Scientists are already exploring combination approaches that pair KRAS inhibitors with other therapies to reduce the likelihood of treatment resistance.
READ ALSO: Researchers Insert a Tumour and Observe Cancer Disappear from the Body
If these efforts prove successful, daraxonrasib could mark the beginning of a new era of more precise, personalised, and effective treatments for pancreatic cancer.
English